查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496766

基底細胞癌治療市場：按類型、途徑、臨床品種、最終用戶分類 - 全球預測 2024-2030

Basal Cell Carcinoma Treatment Market by Type (Drug Therapy, Radiation Therapy, Surgery), Route of Administration (Oral, Parenteral), Clinical Variant, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

基底細胞癌治療市場規模預計2023年為64.7億美元，2024年達69.4億美元，預計2030年將達到108.7億美元，複合年成長率為7.67%。

基底細胞癌（BCC）治療是指用於切除或破壞基底細胞癌的各種醫療介入措施。這種癌症生長緩慢，主要發生在經常暴露在陽光下的皮膚區域，例如臉部、耳朵和頭皮。治療方法取決於腫瘤的大小、位置和嚴重程度，可能包括手術方法，如切除和顯微組織學 (MoHS)、局部藥物、放射線治療和晚期病例的標靶藥物治療。由於紫外線 (UV) 暴露的增加和人口老化，全球皮膚癌（尤其是基底細胞癌）病例數量的增加，極大地推動了對快速有效治療的需求。主要由於公共衛生宣傳活動和媒體報告的增加，人們對皮膚癌症狀、風險和預防措施的治療認知不斷提高，導致越來越多的人尋求基底細胞癌的早期診斷和治療。然而，某些 BSS 治療，例如莫氏手術，需要高度的專業知識和精確度，而缺乏熟練的專業人員對 BCC 治療的採用構成了障礙。此外，副作用以及治療不準確和無效的可能性可能會阻礙患者尋求 BCC 治療。領先者和研究機構對基底細胞癌的遺傳和分子機制正在進行的研究正在導致更有針對性和個性化的治療方法的開發，這些治療方法可能會提高治療效果並減少副作用，這為治療基底細胞癌症開闢了機會。擴大遠距遠端醫療服務並整合人工智慧以提供更好的診斷工具和治療計劃將使專家護理更接近家庭，尤其是在服務不足的社區。

主要市場統計
基準年[2023] 64.7億美元
預測年份 [2024] 69.4億美元
預測年份 [2030] 108.7億美元
複合年成長率（%） 7.67%

區域洞察

以美國和加拿大為中心的美洲地區是一個高度發展的市場，擁有強大的醫療基礎設施和對癌症研究的大量投資。這些地區的消費者受益於早期篩檢計劃，有助於提高意識和早期診斷。患者更喜歡創新的治療方法，例如標靶治療和先進的非侵入性技術。保險範圍極大影響客戶的購買行為，大多數患者選擇衛生當局核准的治療方法。在歐盟 (EU)，醫療保健系統涵蓋廣泛的領域，影響治療的獲得和消費者的購買決策。重點放在成本效率和實證治療。最近的歐盟範圍內的舉措旨在協調癌症治療通訊協定並增加獲得優質治療選擇的機會。關於 BCC 治療的核准、安全性和有效性的嚴格法規創建了標準化框架，並促進了先進和安全治療方法的發展。由於人們對皮膚癌的認知不斷提高以及政府對擴大醫療保健解決方案的支持，亞太地區 BCC 治療市場的前景不斷變化。中國、日本、印度、韓國、新加坡和澳洲正在大力投資腫瘤學研究和醫療基礎設施，重點是開發具有成本效益的治療解決方案。數位醫療措施和遠端醫療的普及在改善 BCC 治療的可近性方面發揮著重要作用。

FPNV定位矩陣

FPNV 定位矩陣對於評估基底細胞癌治療市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對基底細胞癌治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在基底細胞癌治療市場中的地位進行全面評估將有助於公司做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 基底細胞癌的全球盛行率
      • 世界各地對皮膚癌早期診斷和治療的認知正在增強
    • 抑制因素
      • 基底細胞癌治療費用高
    • 機會
      • BCC 治療的進展和改進
      • 遠端醫療和遠距皮膚病學的新興趨勢
    • 任務
      • 對嚴格監管核准的擔憂
  • 市場區隔分析
    • 治療類型：高效藥物治療和手術介入以徹底擴大BCC
    • 給藥途徑：腸外給藥起效迅速，適合治療嚴重的BCC病例。
    • 臨床變異：我們專注於改進和提供針對 BCC 的先進治療方法，以控制硬化性和表面擴散性 BCC 的侵襲性。
    • 最終用戶：政府對醫院和診所設施的擴建和現代化的支持。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章基底細胞癌治療市場：依類型

  • 藥物治療
  • 放射治療
  • 外科手術

第7章基底細胞癌治療市場：依給藥途徑

  • 口服
  • 胃腸外的

第8章依臨床類型分類的基底細胞癌治療市場

  • 結節性基底細胞癌
  • 色素性基底細胞癌
  • 硬化性基底細胞癌
  • 表淺擴散性基底細胞癌

第9章基底細胞癌治療市場：依最終用戶分類

  • 居家護理
  • 醫院/診所
  • 專業中心

第10章美洲基底細胞癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區基底細胞癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲基底細胞癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Elekta 推出 Evo，一款革命性的自我調整CT 直線加速器，可增強癌症治療
    • Medicus Pharma Co., Ltd.透過策略性收購和加強監管策略來推進基底細胞癌治療
    • Medicus Pharma Ltd. 在非侵入性基底細胞癌治療方面的創新進展、監管發展和臨床研究更新。
    • FDA核准的創新設備增強了基層醫療機構中皮膚癌的早期檢測
    • 基底細胞癌非手術治療方法 VP-315 2 期試驗的最終入組和劑量
    • Medison Pharma 與 Regeneron 之間的策略聯盟增強了 Ribtayo 在癌症治療中的全球使用
    • 艾伯維 (AbbVie) 與 Umoja Biopharma 建立策略聯盟，透過創新嵌合體抗原受體 (CAR) T 細胞療法推進腫瘤治療
    • Medicus Pharma 創新 2 期臨床試驗以非侵入性治療基底細胞癌為目標
    • 百時美施貴寶透過策略性收購加強腫瘤產品組合
    • 歐盟核准Ribtayo 治療進行性肺癌擴大了治療可能性
  • 戰略分析和建議
    • 博士健康公司有限公司
    • 百時美施貴寶公司
    • 再生元製藥公司
    • F.霍夫曼拉羅氏股份公司
    • 太陽製藥工業有限公司

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5C6F41F5B0CA

[193 Pages Report] The Basal Cell Carcinoma Treatment Market size was estimated at USD 6.47 billion in 2023 and expected to reach USD 6.94 billion in 2024, at a CAGR 7.67% to reach USD 10.87 billion by 2030.

Basal cell carcinoma (BCC) treatment refers to the various medical interventions used to remove or destroy basal cell carcinomas. This cancer grows slowly and majorly affects areas of the skin that experience frequent sun exposure, such as the face, ears, and scalp. Treatments vary depending on the size, location, and severity of the tumor and include surgical methods such as excision and micrographically oriented histographic (Mohs) surgery, topical medications, radiation therapy, and, in advanced cases, targeted drug therapies. The rising number of skin cancer cases globally, particularly basal cell carcinomas, driven by increased ultraviolet (UV) exposure and aging populations, significantly propels the need for quick and effective treatments. Growing awareness about skin cancer symptoms, risks, and preventive measures, largely due to public health campaigns and increased media coverage, has led more individuals to seek early diagnosis and treatment for BCC. However, certain BSS treatments, such as Mohs surgery, require high levels of expertise and precision, and the lack of skilled professionals poses hurdles to the adoption of BCC treatments. Moreover, the possibility of side effects and inaccurate and ineffective treatment can dissuade patients from seeking BCC treatments. Continued research by key players and research institutions into the genetic and molecular mechanisms underlying basal cell carcinomas opens opportunities for the development of more targeted, personalized therapies that could improve treatment efficacy and reduce side effects. Expanding telemedicine services and integrating artificial intelligence for better diagnostic tools and treatment planning can make expert care more accessible, especially in underserved areas.

KEY MARKET STATISTICS
Base Year [2023] USD 6.47 billion
Estimated Year [2024] USD 6.94 billion
Forecast Year [2030] USD 10.87 billion
CAGR (%) 7.67%

Regional Insights

In the Americas region, particularly the United States and Canada, basal cell carcinoma treatment is a highly advanced market driven by a robust healthcare infrastructure and significant investments in cancer research. Consumers in these regions benefit from early screening programs, which contribute to high awareness levels and early diagnosis. Patients prefer innovative treatments such as targeted therapies and advanced non-invasive technologies. Insurance coverage hugely impacts customer purchasing behavior, with most opting for treatments approved by health authorities. In the European Union, healthcare systems provide extensive coverage, influencing treatment accessibility and consumer purchasing decisions. There is a strong emphasis on cost-efficiency and evidence-based treatments. Recent EU-wide initiatives have aimed to harmonize cancer treatment protocols, increasing the accessibility of high-quality treatment options. Stringent regulations pertaining to the approval, safety, and efficacy of BCC treatments create a standardized framework and lead to the development of highly advanced and safe therapies. The APAC region presents an evolving landscape for the BCC treatment market, owing to growing awareness about skin cancers and government support for extending access to healthcare solutions. China, Japan, India, South Korea, Singapore, and Australia Japan offer significant investments in oncology research and healthcare infrastructure, emphasizing developing cost-effective treatment solutions. Digital health initiatives and the proliferation of telemedicine have played a key role in improving access to BCC treatment.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Basal Cell Carcinoma Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Prevalence of basal cell carcinoma worldwide
      • Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • Market Restraints
      • High cost of basal cell carcinoma treatment
    • Market Opportunities
      • Advancements and improvements in BCC treatment
      • Emerging trend of telemedicine and teledermatology
    • Market Challenges
      • Concerns associated with stringent regulatory approval
  • Market Segmentation Analysis
    • Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Basal Cell Carcinoma Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Basal Cell Carcinoma Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment

Elekta, a global company in precision radiation therapy solutions, unveiled its Evo CT-linac, offline and online adaptive radiation therapy, enhancing the precision of image-guided treatments. This state-of-the-art system combines high-definition AI-assisted imaging with versatile radiation therapy modalities, catering to individualized patient care. [Published On: 2024-05-03]

Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies

Medicus Pharma Ltd., a biotech holding company, made significant strides in advancing therapies for basal cell carcinoma (BCC), following its acquisition of SkinJect, Inc. SkinJect, a Medicus subsidiary, holds an exclusive license for a revolutionary Dissolvable Microneedle Array drug delivery system. Over the past six months, Medicus Pharma Ltd. has expedited the FDA regulatory approval process for the SkinJect transdermal patch designed to treat BCC. [Published On: 2024-04-25]

Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies

Medicus Pharma Ltd. has received feedback from the U.S. Food and Drug Administration (FDA) regarding their new treatment method for basal cell carcinoma (BCC), which involves the use of micro-array needles containing doxorubicin (D-MNA). The company planned to boost clinical trials as a significant step toward establishing a ground-breaking, non-invasive treatment option for BCC. [Published On: 2024-03-31]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Basal Cell Carcinoma Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Basal Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Almirall, LLC, Amgen Inc., Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., Glenmark Pharmaceuticals Limited, LEO Pharma A/S, Medicus Pharma Ltd., Medivir AB, OncoBeta GmbH, Perrigo Company PLC, Redx Pharma PLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., SkinCure Oncology, Sol-Gel Technologies Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Basal Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Drug Therapy
      • Immunotherapy
      • Oral Medications
      • Targeted Therapy
      • Topical Medications
    • Radiation Therapy
    • Surgery
  • Route of Administration
    • Oral
    • Parenteral
  • Clinical Variant
    • Nodular Basal Cell Carcinoma
    • Pigmented Basal Cell Carcinoma
    • Sclerosing Basal Cell Carcinoma
    • Superficial Spreading Basal Cell Carcinoma
  • End-Users
    • Homecare
    • Hospitals & Clinics
    • Specialty Centres
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Illinois
        • Massachusetts
        • New Jersey
        • New York
        • North Carolina
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of basal cell carcinoma worldwide
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment of skin cancer globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of basal cell carcinoma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and improvements in BCC treatment
      • 5.1.3.2. Emerging trend of telemedicine and teledermatology
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with stringent regulatory approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: High effectiveness of drug therapies and surgery interventions in escalating the BCC completely
    • 5.2.2. Route of Administration: Rapid effect provided by parenteral administration leading to its preference for managing severe BCC cases
    • 5.2.3. Clinical Variant: Focused efforts to improve and provide advanced treatments for sclerosing and superficial spreading BCC to manage its aggressive nature
    • 5.2.4. End-Users: Government support for expanding and modernizing hospital and clinic facilities
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Basal Cell Carcinoma Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Drug Therapy
  • 6.3. Radiation Therapy
  • 6.4. Surgery

7. Basal Cell Carcinoma Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Basal Cell Carcinoma Treatment Market, by Clinical Variant

  • 8.1. Introduction
  • 8.2. Nodular Basal Cell Carcinoma
  • 8.3. Pigmented Basal Cell Carcinoma
  • 8.4. Sclerosing Basal Cell Carcinoma
  • 8.5. Superficial Spreading Basal Cell Carcinoma

9. Basal Cell Carcinoma Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals & Clinics
  • 9.4. Specialty Centres

10. Americas Basal Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Basal Cell Carcinoma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Basal Cell Carcinoma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Elekta Unveils Evo, a Groundbreaking Adaptive CT-Linac for Enhanced Cancer Treatment
    • 13.3.2. Medicus Pharma Ltd. Advances Basal Cell Carcinoma Treatment Through Strategic Acquisitions and Enhanced Regulatory Strategies
    • 13.3.3. Innovative Advances in Non-Invasive Basal Cell Carcinoma Treatment by Medicus Pharma Ltd., Update on Regulatory Development and Clinical Studies
    • 13.3.4. Groundbreaking FDA-Cleared Device Enhances Early Detection of Skin Cancer in Primary Care Settings
    • 13.3.5. Final Enrollment and Dosing in Phase 2 Trial of a Non-Surgical Treatment VP-315 for Basal Cell Carcinoma
    • 13.3.6. Strategic Collaboration Between Medison Pharma and Regeneron to Enhance Global Access to Libtayo for Cancer Treatment
    • 13.3.7. Strategic Collaboration between AbbVie and Umoja Biopharma to Advance Oncology Treatment with Innovative Chimeric Antigen Receptor (CAR) T-cell Therapies
    • 13.3.8. Innovative Phase 2 Clinical Study by Medicus Pharma Targets Non-Invasive Treatment for Basal Cell Carcinoma
    • 13.3.9. Bristol Myers Squibb Enhances Oncology Portfolio Through Strategic Acquisitions
    • 13.3.10. EU Approval of Libtayo for Advanced Lung Cancer Broadens Treatment Horizons
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Bausch Health Companies Inc.
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Regeneron Pharmaceuticals, Inc.
    • 13.4.4. F. Hoffmann-La Roche AG
    • 13.4.5. Sun Pharmaceutical Industries Ltd.

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BASAL CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BASAL CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BASAL CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BASAL CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BASAL CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TOPICAL MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY NODULAR BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY PIGMENTED BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SCLEROSING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SUPERFICIAL SPREADING BASAL CELL CARCINOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY DRUG THERAPY, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINICAL VARIANT, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY BASAL CELL CARCINOMA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL BASAL CELL CARCINOMA TREATMENT MARKET SIZE, B